Psoriatic Arthritis - Pipeline Review, H2 2017

  • ID: 4429845
  • Report
  • 244 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 3SBio Inc
  • Alteogen Inc
  • Eli Lilly and Co
  • Genor BioPharma Co Ltd
  • Morphotek Inc
  • Pfizer Inc
  • MORE
Psoriatic Arthritis - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Psoriatic Arthritis - Pipeline Review, H2 2017, provides an overview of the Psoriatic Arthritis (Musculoskeletal Disorders) pipeline landscape.

Psoriatic arthritis is a form of arthritis that affects some people who have psoriasis. Symptoms include swollen fingers and toes, foot pain and lower back pain. Risk factors include age, family history and psoriasis. Treatment includes NSAIDs, immunosuppressants and surgery.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Psoriatic Arthritis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 5, 8, 10, 1, 24, 9 and 3 respectively.

Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Psoriatic Arthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Psoriatic Arthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Psoriatic Arthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Psoriatic Arthritis (Musculoskeletal Disorders)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Psoriatic Arthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3SBio Inc
  • Alteogen Inc
  • Eli Lilly and Co
  • Genor BioPharma Co Ltd
  • Morphotek Inc
  • Pfizer Inc
  • MORE
Introduction

Psoriatic Arthritis - Overview

Psoriatic Arthritis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Psoriatic Arthritis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Psoriatic Arthritis - Companies Involved in Therapeutics Development

3SBio Inc

AbbVie Inc

AbGenomics International Inc

Aclaris Therapeutics Inc

Adello Biologics LLC

Allergan Plc

Alteogen Inc

Amgen Inc

Biocon Ltd

Bionovis SA

Coherus BioSciences Inc

Eli Lilly and Co

Formycon AG

Forward Pharma AS

Fresenius SE & Co KGaA

Galapagos NV

Genor BioPharma Co Ltd

Immunwork Inc

Innovent Biologics Inc

Johnson & Johnson

KPI Therapeutics Inc

Morphotek Inc

Mycenax Biotech Inc

Nichi-Iko Pharmaceutical Co Ltd

Novo Nordisk AS

Nuevolution AB

Oncobiologics Inc

Pfizer Inc

Reliance Life Sciences Pvt Ltd

Rigel Pharmaceuticals Inc

Sandoz International GmbH

Sun Pharma Advanced Research Company Ltd

SynAct Pharma AB

UCB SA

Xbrane Biopharma AB

Psoriatic Arthritis - Drug Profiles

AbGn-168H - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

adalimumab biosimilar - Drug Profile

AGR-131 - Drug Profile

AK-101 - Drug Profile

AK-111 - Drug Profile

AP-1189 - Drug Profile

apremilast - Drug Profile

ATI-450 - Drug Profile

baricitinib - Drug Profile

bimekizumab - Drug Profile

certolizumab pegol - Drug Profile

certolizumab pegol biosimilar - Drug Profile

clazakizumab - Drug Profile

dalazatide - Drug Profile

dimethyl fumarate - Drug Profile

DNX-114 - Drug Profile

DNX-514 - Drug Profile

etanercept - Drug Profile

etanercept biosimilar - Drug Profile

etanercept biosimilar - Drug Profile

etanercept biosimilar - Drug Profile

etanercept biosimilar - Drug Profile

etanercept biosimilar - Drug Profile

etanercept biosimilar - Drug Profile

etanercept biosimilar - Drug Profile

etanercept biosimilar - Drug Profile

filgotinib - Drug Profile

golimumab biosimilar - Drug Profile

golimumab biosimilar - Drug Profile

GSK-3050002 - Drug Profile

guselkumab - Drug Profile

HEISCO-III-002 - Drug Profile

infliximab biosimilar - Drug Profile

infliximab biosimilar - Drug Profile

infliximab biosimilar - Drug Profile

infliximab biosimilar - Drug Profile

infliximab biosimilar - Drug Profile

infliximab biosimilar - Drug Profile

INV-17 - Drug Profile

ixekizumab - Drug Profile

liraglutide - Drug Profile

risankizumab - Drug Profile

Small Molecule to Antagonize ROR-Gamma for Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis - Drug Profile

Small Molecule to Inhibit IRAK1/4 for Arthritis and Psoriasis - Drug Profile

Small Molecules to Antagonize RORgamma for Rheumatoid Arthritis, Inflammatory Bowel Disease, Dermatology and Psoriatic Arthritis - Drug Profile

TE-2122 - Drug Profile

TE-2158 - Drug Profile

tildrakizumab - Drug Profile

tofacitinib citrate - Drug Profile

upadacitinib tartrate - Drug Profile

ustekinumab biosimilar - Drug Profile

ustekinumab biosimilar - Drug Profile

ustekinumab biosimilar - Drug Profile

VTP-43742 - Drug Profile

Psoriatic Arthritis - Dormant Projects

Psoriatic Arthritis - Discontinued Products

Psoriatic Arthritis - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Psoriatic Arthritis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Psoriatic Arthritis - Pipeline by 3SBio Inc, H2 2017

Psoriatic Arthritis - Pipeline by AbbVie Inc, H2 2017

Psoriatic Arthritis - Pipeline by AbGenomics International Inc, H2 2017

Psoriatic Arthritis - Pipeline by Aclaris Therapeutics Inc, H2 2017

Psoriatic Arthritis - Pipeline by Adello Biologics LLC, H2 2017

Psoriatic Arthritis - Pipeline by Allergan Plc, H2 2017

Psoriatic Arthritis - Pipeline by Alteogen Inc, H2 2017

Psoriatic Arthritis - Pipeline by Amgen Inc, H2 2017

Psoriatic Arthritis - Pipeline by Biocon Ltd, H2 2017

Psoriatic Arthritis - Pipeline by Bionovis SA, H2 2017

Psoriatic Arthritis - Pipeline by Coherus BioSciences Inc, H2 2017

Psoriatic Arthritis - Pipeline by Eli Lilly and Co, H2 2017

Psoriatic Arthritis - Pipeline by Formycon AG, H2 2017

Psoriatic Arthritis - Pipeline by Forward Pharma AS, H2 2017

Psoriatic Arthritis - Pipeline by Fresenius SE & Co KGaA, H2 2017

Psoriatic Arthritis - Pipeline by Galapagos NV, H2 2017

Psoriatic Arthritis - Pipeline by Genor BioPharma Co Ltd, H2 2017

Psoriatic Arthritis - Pipeline by Immunwork Inc, H2 2017

Psoriatic Arthritis - Pipeline by Innovent Biologics Inc, H2 2017

Psoriatic Arthritis - Pipeline by Johnson & Johnson, H2 2017

Psoriatic Arthritis - Pipeline by KPI Therapeutics Inc, H2 2017

Psoriatic Arthritis - Pipeline by Morphotek Inc, H2 2017

Psoriatic Arthritis - Pipeline by Mycenax Biotech Inc, H2 2017

Psoriatic Arthritis - Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H2 2017

Psoriatic Arthritis - Pipeline by Novo Nordisk AS, H2 2017

Psoriatic Arthritis - Pipeline by Nuevolution AB, H2 2017

Psoriatic Arthritis - Pipeline by Oncobiologics Inc, H2 2017

Psoriatic Arthritis - Pipeline by Pfizer Inc, H2 2017

Psoriatic Arthritis - Pipeline by Reliance Life Sciences Pvt Ltd, H2 2017

Psoriatic Arthritis - Pipeline by Rigel Pharmaceuticals Inc, H2 2017

Psoriatic Arthritis - Pipeline by Sandoz International GmbH, H2 2017

Psoriatic Arthritis - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017

Psoriatic Arthritis - Pipeline by SynAct Pharma AB, H2 2017

Psoriatic Arthritis - Pipeline by UCB SA, H2 2017

Psoriatic Arthritis - Pipeline by Xbrane Biopharma AB, H2 2017

Psoriatic Arthritis - Dormant Projects, H2 2017

Psoriatic Arthritis - Dormant Projects, H2 2017 (Contd..1), H2 2017

Psoriatic Arthritis - Discontinued Products, H2 2017

List of Figures

Number of Products under Development for Psoriatic Arthritis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 3SBio Inc
  • AbbVie Inc
  • AbGenomics International Inc
  • Aclaris Therapeutics Inc
  • Adello Biologics LLC
  • Allergan Plc
  • Alteogen Inc
  • Amgen Inc
  • Biocon Ltd
  • Bionovis SA
  • Coherus BioSciences Inc
  • Eli Lilly and Co
  • Formycon AG
  • Forward Pharma AS
  • Fresenius SE & Co KGaA
  • Galapagos NV
  • Genor BioPharma Co Ltd
  • Immunwork Inc
  • Innovent Biologics Inc
  • Johnson & Johnson
  • KPI Therapeutics Inc
  • Morphotek Inc
  • Mycenax Biotech Inc
  • Nichi-Iko Pharmaceutical Co Ltd
  • Novo Nordisk AS
  • Nuevolution AB
  • Oncobiologics Inc
  • Pfizer Inc
  • Reliance Life Sciences Pvt Ltd
  • Rigel Pharmaceuticals Inc
  • Sandoz International GmbH
  • Sun Pharma Advanced Research Company Ltd
  • SynAct Pharma AB
  • UCB SA
  • Xbrane Biopharma AB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll